

Certificate of Analysis

PTP MEG1, active

(Recombinant enzyme expressed in *E. coli* cells)

Item # 14-642

Lot # 1987060

Product Description: N-terminal GST-tagged, recombinant, human PTP MEG1, amino acids 423–end, expressed in *E. coli* cells. Purified using glutathione agarose. Purity 56% by SDS-PAGE and Coomassie blue staining. MW = 83.1kDa.

Specific Activity (lot# 1987060): 239U/mg, where one unit of PTP MEG1 activity is defined as the release of 1nmol of phosphate per minute from the phosphorylated substrate 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) at room temperature.

Formulation: 1.09mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Phosphatase Assay: 0–11ng of this lot of enzyme dephosphorylated 200μM DiFMUP in the assay described on page two. Assay background was subtracted from the actual Fluorescence Intensity (FI) to yield the results shown below. Quantification of FI was against a 6,8-difluoro-7-hydroxy-4-methylcoumarin (DiFMU) standard curve.



MS Tryptic Fingerprint: Confirmed identity as PTP MEG1 with the translated sequence listed on page three.



Certificate of Analysis

Phosphatase Assay Protocol

Stock Solutions:

1. **Reaction Buffer:** 60mM Hepes pH7.2, 150mM NaCl, 1mM EDTA, 0.17mM DTT, 0.83 (v/v)% glycerol, 0.017 (w/v)% BSA, 0.002% Brij-35.
2. 500µM DiFMUP (Molecular Probes Catalogue# D6567) in water.
3. 100mM sodium orthovanadate.
4. 500µM DiFMU (Molecular Probes Catalogue# D6566) in water for the calibration curve.

Assay Procedure:

1. Dilute **PTP-MEG1** in reaction buffer and use 0–11ng in 15µl per assay point.
2. Add 10µl DiFMUP 500µM stock solution (200µM final assay concentration).
3. Incubate for 30 minutes at room temperature.
4. Stop the reaction by adding 5µl of 100mM sodium orthovanadate.
5. Read FI using an appropriate reader (Excitation 340nm; Emission 450nm).
6. Subtract the zero enzyme values from each FI reading and calculate the enzyme activity by conversion to nmoles product formed using a DiFMU standard calibration curve.

Preparation of DiFMU Standard Calibration Curve

1. Prepare a series of standards according to the table below:

Volume of 100µM DiFMU (product)	Volume of 100µM DiFMUP (substrate)	pmoles DiFMU per well	Represents Substrate Conversion of:
0µl	100µl	0	0%
1µl	99µl	25	1%
2µl	98µl	50	2%
3µl	97µl	75	3%
4µl	96µl	100	4%
5µl	95µl	125	5%
8µl	92µl	200	8%
12µl	88µl	300	12%

2. Add 25µl of each prepared standard to triplicate wells and read fluorescence intensity using an appropriate reader (Excitation 358nm, Emission 455nm).

Note: Substrate conversion above 15% introduces the possibility of skewing the curve so that calculated specific activity will be less than actual specific activity. This substrate limitation kinetic varies with each enzyme and may be determined by plotting product formed per unit time versus enzyme concentration. At low enzyme concentrations, the rate of product formation will be proportional to the enzyme concentration used. This relationship plateaus at higher enzyme concentrations.

Certificate of Analysis

PTP MEG1 Sequence Information

<u>Protein</u>	Human PTPMEG-1
<u>Tags</u>	N-Terminal GST
<u>Native sequence</u>	M227 of the recombinant protein is equivalent to M423 of human PTPMEG-1
<u>Accession number</u>	GenBank NM_002830

Recombinant PTPMEG-1 amino acid sequence:

```

1  MSPILGYWKI  KGLVQPTRLL  LEYLEEKYEE  HLYERDEGDK  WRNKKFELGL  EFPNLPYYID
61  GDVKLTQSMa  IIRYIADKHN  MLGGCPKERA  EISMLEGAVL  DIRYGVSRIA  YSKDFETLKV
121 DFLSKLPEML  KMFEDRLCHK  TYLNGDHVTH  PDFMLYDALD  VVLYMDPMCL  DAFPKLVCFK
181 KRIEAIQID  KYLKSSKYIA  WPLQGQWATF  GGGDHPPKSD  LVPRGSMVHT  SPSEVFNQR
241 SPSTQANSI  VLESSPSQET  PGDGKPPALP  PKQSKKNSWN  QIHYSHSQQD  LESHINETFD
301 IPSSPEKPTP  NGGIPHDNLV  LIRMKPDENG  RFGFNVKGGY  DQKMPVIVSR  VAPGTPADLC
361 VPRLNEGDQV  VLINGRDIAE  HTHDQVVLFI  KASCERHSGE  LMLLVRPNAV  YDVVEEKLEN
421 EPDFQYIPEK  APLDSVHQDD  HSLRESMIQL  AEGLITGTVL  TQFDQLYRKK  PGMTMSCAKL
481 PQNISKNNRY  DISPYDATRV  ILKGNEDYIN  ANYINMEIPS  SSIINQYIAC  QGPLPHTCTD
541 FWQMTWEQGS  SMVVMLTTQV  ERGRVKCHQY  WPEPTGSSSY  GCYQVTCHSE  EGN TAYIFRK
601 MTLFNQEKNE  SRPLTQIQYI  AWPDHGVPDD  SSDFLDFVCH  VRNKRAGKEE  PVVVHCSAGI
661 GRTGVLITME  TAMCLIECNQ  PVPPLDIVRT  MRDQRAMMIQ  TPSQYRFVCE  AILKVYEEGF
721 VKPLTTSTNK

```

Recombinant PTPMEG-1 nucleotide sequence:

```

1  atgtccccta  tactaggtta  ttggaataat  aagggccttg  tgcaaccac  tcgacttctt
61  ttggaatatc  ttgaagaaaa  atatgaagag  catttgatatg  agcgcatga  aggtgataaa
121  tggcgaaaca  aaaagtttga  attgggtttg  gagtttccca  atcttcctta  ttatattgat
181  ggtgatgta  aattaacaca  gtctatggcc  atcatagctt  atatactga  caagcacaac
241  atgttgggtg  gttgtccaaa  agagcgtgca  gagatttcaa  tgcttgaagg  agcggttttg
301  gatattagat  acggtgtttc  gagaattgca  tatagtaaag  actttgaaac  tctcaaagtt
361  gattttctta  gcaagctacc  tgaaatgctg  aaaatgttcg  aagatcgttt  atgtcataaa
421  acatatttaa  atggtgatca  tgtaacccat  cctgacttca  tggttgatga  cgctcttgat
481  gttgttttat  acatggaccc  aatgtgcctg  gatgcgttcc  caaaattagt  ttgttttaaa
541  aaacgtattg  aagctatccc  acaaattgat  aagtacttga  aatccagcaa  gtatatagca
601  tggcctttgc  agggctggca  agccacgttt  ggtggtggcg  accatcctcc  aaaatcggat
661  ctggttccgc  gtggatccat  ggttcatact  tccccagcga  aagtgtttgt  aaatcagaga
721  tctccgcat  caacacacat  taatagcatt  gttctggaat  catcaccatc  acaagagacc
781  cctggagatg  ggaagcctcc  agctttacca  cccaaacagt  caaagaaaaa  cagttggaac
841  caaattcatt  attcacattc  gcaacaagat  ctagaaagtc  atattaatga  aacatttgat
901  attccatctt  ctccctgaaa  acccactcct  aatggtggta  ttccacatga  taatcttgtc
961  ctaatcagaa  tgaaacctga  tgaaaatggg  aggtttggat  tcaatgtaaa  gggaggatat
1021 gatcagaaga  tgctgtgat  tgtgtctcga  gtagcaccag  gaacacctgc  tgacctctgt
1081 gtccctagac  tgaatgaagg  ggaccaagtt  gtactgatca  atggtcgga  cattgcagaa
1141 cacactcatg  atcaggttgt  gctgtttatt  aaagctagtt  gtgagagaca  ttctggggaa
1201 ctcatgcttc  tagttcgacc  taatgctgta  tatgatgtag  tggaagaaaa  gctagaaaat
1261 gagccagatt  tccagtatat  tcctgagaaa  gccccactag  atagtgtgca  tcaggatgac
1321 cattccctgc  gggagtcaat  gatccagcta  gctgaggggc  ttatcactgg  aacagtcctg
1381 acacagtttg  atcaactgta  tcggaaaaaa  cctggaatga  caatgtcctg  tgccaaatta
1441 cctcagaata  tttccaaaaa  tagatacaga  gatatttcgc  cttatgatgc  cacacgggtc
1501 attttaaaag  gtaatgaaga  ctacatcaat  gcgaactata  taaatatgga  aattccttct
1561 tccagcatta  taaatcagta  cattgcttgt  caagggccat  taccacacac  ttgtacagat
1621 ttttggcaga  tgacttggga  acaaggctcc  tctatggttg  taatgttgac  cacacaagtt
1681 gaacgtggca  gagttaaatg  tcaccaatat  tggccagaac  ccacaggcag  ttcattctat

```

Certificate of Analysis

```
1741 ggatgctacc aagttacctg ccactctgaa gaaggaaaca ctgcctatat cttcaggaag
1801 atgaccctat ttaaccaaga gaaaaatgaa agtcgtccac tcactcagat ccagtacata
1861 gcctggcctg accatggagt ccctgatgat tcgagtgact ttctagattt tgtttgtcat
1921 gtacgaaaca agagggtgg caaggaagaa cccgttggtg tccattgcag tgctggaatc
1981 ggaagaactg gggttcttat tactatggaa acagccatgt gtctcattga atgcaatcag
2041 ccagtttatc cactagatat tgtaagaaca atgagagatc agcgagccat gatgatccaa
2101 acacctagtc aatacagatt tgtatgtgaa gctattttga aagtttatga agaaggcttt
2161 gttaaaccct taacaacatc aacaaataaa taa
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.